Novo Nordisk

Novo Nordisk

company Denmark

Novo Nordisk is a Danish multinational pharmaceutical company that specializes in diabetes care and hormone replacement therapies. Founded in 1923, the company is known for its innovative insulin products and GLP-1 receptor agonists, such as Ozempic, which are used for managing diabetes and aiding in weight loss. Novo Nordisk has a strong commitment to research and development, particularly in the fields of diabetes, obesity, and hemophilia.

Global Media Ratings
Dominance
0.00%
Persistence
0 wks
Reach
52,209
Power
1,019$
Sentiment
6.23
Countries Mentioned
Country Mentions Sentiment Dominance + Persistence x Population = Reach x GDP (millions) = Power
Bulgaria 1 8.00 0.06% +0% 6,948,445 4,271 $69,000 42$
Estonia 1 5.00 0.04% +0% 1,326,539 499 $31,000 12$
Argentina 1 6.00 0.04% +0% 45,195,774 17,942 $450,000 179$
Ecuador 1 7.00 0.04% +0% 17,643,060 7,038 $108,000 43$
Italy 1 6.00 0.04% +0% 60,461,826 22,460 $2,000,000 743$
Totals 5 131,575,644 52,210 $2,658,000 1,019$
Interactive World Map

Each country's color is based on "Mentions" from the table above.

Recent Mentions

Argentina Argentina: Novo Nordisk is the owner of the original Ozempic and has announced the arrival of Wegovy in Argentina. 6

Clarín: Sale el "Ozempic nacional" inyectable en pleno plan oficial para bajar el precio de los medicamentos

Denmark Denmark: Novo Nordisk has decided to significantly reduce the price of the weight loss drug Wegovy in the US market. 8

Politiken: Novo Nordisk mere end halverer prisen på Wegovy i USA